FDA Warning Letter: Major CGMP & Aseptic Processing Violations 483

FDA Warning Letter: Major CGMP, Aseptic Processing and Microbiological Contamination Violations

This FDA Warning Letter highlights significant violations of Current Good Manufacturing Practice (CGMP) requirements identified during an FDA inspection of a manufacturer of sterile prescription and over-the-counter (OTC) drug products.

FDA determined that the firm’s manufacturing methods, facilities, and controls for manufacturing, processing, packing, and holding drug products did not comply with applicable CGMP requirements under 21 CFR Parts 210 and 211.

As a result, the drug products manufactured by the firm were considered adulterated under Section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act).

The inspection identified serious deficiencies involving:

Environmental monitoring
Personnel monitoring
Aseptic processing
ISO 5 areas
Microbiological contamination
Restricted Access Barrier System (RABS) design
Unidirectional airflow
Dynamic smoke studies
Aseptic technique
Cleanroom behavior
Media fill validation
Water for Injection (WFI) monitoring
Microorganism identification
CAPA
Quality Unit oversight
Facility and equipment design
Contamination-control strategy

This FDA Warning Letter demonstrates the importance of maintaining robust contamination-control systems and effective quality oversight when manufacturing sterile drug products.

Key Findings in the FDA Warning Letter

The major observations described in this FDA Warning Letter can be summarized as follows:

Inadequate environmental and personnel monitoring.
Repeated microbiological contamination in ISO 5 areas.
Failure to adequately investigate microbiological excursions and adverse trends.
Deficiencies in RABS and aseptic processing line design.
Inadequate dynamic smoke studies.
Poor aseptic technique and cleanroom behavior.
Inadequate media fill/process simulation studies.
Inadequate investigation of objectionable microorganisms.
Insufficient contamination-control CAPA.
Inadequate Quality Unit and management oversight.
Failure to adequately evaluate facility and process design risks.
Insufficient evidence demonstrating sustained aseptic process control.

1. Inadequate Environmental Monitoring and Personnel Monitoring

One of the most significant findings in the FDA Warning Letter involved deficiencies in the firm’s Environmental Monitoring (EM) and Personnel Monitoring (PM) programs.

The facility manufactured sterile products using aseptic processing, making effective environmental and personnel monitoring essential to contamination control.

FDA determined that the firm’s monitoring program did not adequately cover significant locations within classified areas.

For example, important contamination-risk locations, including items such as phones used in aseptic processing areas, were not sufficiently monitored.

FDA also determined that some environmental monitoring procedures were inadequate.

In addition, the media used to support the environmental monitoring program was observed to have deficiencies, including cracked media that could compromise the ability to recover and evaluate microorganisms.

2. Repeated Microbiological Contamination in ISO 5 Areas

The FDA Warning Letter identified repeated recovery of microorganisms from ISO 5 areas between 2023 and 2025.

Microorganisms were recovered from:

Air
Surfaces
Personnel

Some results were reported as out-of-limit (OOL). Of particular concern was the recovery of Gram-negative organisms such as:

Serratia marcescens
Stenotrophomonas maltophilia

These organisms can be associated with environmental or water-related contamination concerns.

FDA expressed concern that the firm continued production without implementing adequate CAPA to address persistent microbiological contamination in critical ISO 5 environments.

For sterile manufacturing, repeated recovery of microorganisms should trigger appropriate investigation, risk assessment, trend analysis, root-cause investigation, and effective corrective and preventive actions.

3. Failure to Adequately Investigate Microbiological Trends

Another important issue highlighted by the FDA Warning Letter was the firm’s failure to adequately investigate microbiological departures and adverse trends. FDA noted deficiencies involving:

Environmental monitoring
Personnel monitoring
Water for Injection systems
Microorganism identification
Persistent microbiological recoveries
Adverse trends
Action-limit excursions

Investigations did not adequately evaluate the repeated recovery of microorganisms over time. FDA also identified concerns regarding microorganism identification. Some microorganisms recovered from the facility included:

Pseudomonas aeruginosa
Aspergillus brasiliensis

FDA noted that microorganisms from the same genus and species were also recovered from certain consumer complaint samples.

This finding increases the importance of a scientifically sound investigation linking environmental, personnel, water, product, and complaint microbiological data where appropriate.

4. Aseptic Processing and Manufacturing Design Deficiencies

The FDA Warning Letter also identified deficiencies in the design and control of the firm’s aseptic processing operations.

The firm’s Restricted Access Barrier System (RABS) line had design concerns, including equipment placement and ergonomic difficulties during aseptic operations.

FDA also identified insufficient barrier protection in certain areas.

These design deficiencies can increase the risk of contamination when operators perform interventions or manipulate sterile components.

Aseptic processing equipment and cleanroom design should minimize:

Human intervention
Operator movement
Difficult manipulations
Unnecessary exposure of sterile components
Disruption of unidirectional airflow
Transfer of contamination into critical areas

5. Inadequate Dynamic Smoke Studies

A significant observation in the FDA Warning Letter involved dynamic smoke studies.

FDA determined that the firm’s smoke studies did not adequately demonstrate unidirectional airflow protection across multiple aseptic processing lines.This included situations involving:

Equipment setup
Equipment assembly
Filling operations
Aseptic interventions
Dynamic operator activities

Smoke studies are important because they provide visual evidence of airflow behavior in critical processing areas.

For sterile operations, airflow visualization should demonstrate that critical surfaces and sterile product-contact components remain adequately protected during routine and representative interventions.

FDA therefore requested a critical evaluation of airflow unidirectionality with assistance from a qualified consultant.

The smoke studies should be performed under appropriate dynamic conditions after remediation of the aseptic operation.

6. Sterility Testing Alone Cannot Demonstrate Process Control

An important lesson from this FDA Warning Letter is that a passing sterility test does not, by itself, demonstrate that an aseptic manufacturing process is adequately controlled.

Sterility testing is an important quality-control test for products intended to be sterile. However, sterility testing is only one element of a comprehensive contamination-control strategy. A robust sterile manufacturing system should incorporate:

Facility design
HVAC and airflow control
ISO classification
Personnel qualification
Aseptic technique
Environmental monitoring
Personnel monitoring
Cleaning and disinfection
Equipment qualification
Process validation
Media fills
Sterilization controls
Microbiological monitoring
Quality Unit oversight

The FDA Warning Letter emphasizes that quality must be built into the manufacturing process rather than relying solely on end-product testing.

7. Poor Aseptic Technique and Cleanroom Behavior

The FDA inspection identified multiple examples of poor aseptic practices. Operators were observed performing activities that could potentially compromise sterile product protection. Examples included:

Reaching over exposed containers during interventions.
Inadequate disinfection of equipment or components.
Blocking unidirectional airflow.
Contact with sterile portions of aseptic instruments.
Improper handling of sterile components.
Improper transfer of sterile materials.
Inappropriate handling of waste near the processing line.

These practices demonstrate why aseptic behavior and operator qualification are critical components of sterile manufacturing.

Personnel working in ISO 5 and surrounding classified areas should understand how their movements and interventions can affect airflow and contamination risk.

8. Inadequate Media Fill / Aseptic Process Simulation

The FDA Warning Letter also identified deficiencies in the firm’s media fill program.

FDA determined that the number of units used in certain media fills was substantially smaller than the firm’s commercial aseptic batch sizes.

Therefore, the simulations did not sufficiently represent the contamination risks associated with actual commercial production.

Media fills should be appropriately designed to simulate routine and worst-case aseptic processing conditions. Relevant factors may include:

Commercial batch size
Processing duration
Number of operators
Operator interventions
Equipment setup
Line configuration
Container handling
Aseptic manipulations
Shift changes
Environmental conditions
Equipment interventions

9. Media Fill Failure

The inspection also identified a documented media fill failure on one production line in July 2025. Two units demonstrated microbiological contamination involving:

Neovaginatispora magiferae
Geodermatophilus obscurus

A media fill failure requires a thorough investigation and appropriate evaluation of potential impact on the aseptic process. The investigation should consider:

Root cause
Personnel practices
Equipment
Facility design
Environmental monitoring
Interventions
Cleaning and disinfection
Sterilization
Material transfer
Previous media fills
Related commercial batches

The investigation should lead to scientifically justified CAPA where appropriate.

10. Water for Injection and Microbiological Control

The FDA Warning Letter also raised concerns regarding the investigation of microbiological departures and adverse trends associated with the firm’s Water for Injection (WFI) system.

WFI is a critical utility in sterile pharmaceutical manufacturing. A robust WFI monitoring program should consider:

Sampling locations
Sampling frequency
Microbial limits
Alert and action levels
Trend analysis
Microorganism identification
Sanitization
System design
Maintenance
Temperature
Distribution loops
Points of use

Repeated microbiological excursions should be investigated comprehensively rather than treated as isolated events.

11. Inadequate CAPA

The FDA inspection indicated that the firm did not adequately implement CAPA to address persistent microbiological contamination. An effective CAPA system should identify the true root cause of the problem. Simply adding training or changing an SOP may not be sufficient if the underlying problem involves:

Facility design
Equipment design
Airflow
Personnel practices
Process design
Material flow
Environmental controls
Management oversight
Quality system weaknesses

The FDA Warning Letter therefore emphasizes the need for systemic CAPA rather than superficial corrective actions.

12. Comprehensive Contamination Risk Assessment

FDA requested an independent and comprehensive assessment of contamination hazards associated with the firm’s aseptic processes, equipment, and facilities. The assessment should consider:

Human Interactions

Evaluate all human interventions within ISO 5 areas and identify opportunities to reduce or eliminate manual intervention.

Equipment Suitability

Evaluate:

Equipment reliability
Equipment capability
Ergonomics
Equipment placement
Cleanability
Maintenance
Available cleanroom space

Airflow

Assess:

Air volume
Airflow direction
Unidirectional airflow
Air changes
Critical-area protection
Dynamic airflow conditions

Facility Layout

Evaluate whether the facility layout supports effective contamination control.

Personnel Flow

Review movement of personnel through:

Cleanrooms
Gowning areas
Support rooms
Aseptic processing areas

Material Flow

Evaluate movement and transfer of:

Sterile components
Raw materials
Packaging materials
Equipment
Waste

The risk assessment should result in clearly defined CAPA and remediation actions.

13. Remediation of Aseptic Processing Operations

The FDA Warning Letter requested a detailed remediation plan addressing deficiencies in aseptic processing. The remediation plan should include:

Specific improvements
Responsible functions
Completion timelines
Facility modifications
Equipment modifications
Cleanroom improvements
RABS improvements
Airflow improvements
Qualification requirements
Validation requirements
Personnel training
Environmental monitoring improvements
Media fill strategy
CAPA effectiveness checks

Extensive modifications to aseptic processing lines and cleanrooms should be appropriately qualified and validated before routine commercial production resumes.

14. Quality Unit and Management Oversight

The inspection identified significant concerns regarding the firm’s overall quality system.

The FDA Warning Letter stated that the firm did not appear to operate an effective quality system consistent with CGMP requirements. FDA identified concerns regarding:

Management oversight
Quality Unit authority
Quality Unit responsibilities
Production oversight
Aseptic process control
Investigation effectiveness
CAPA effectiveness

Executive management should therefore conduct a comprehensive review of the firm’s manufacturing operations. The review should determine whether quality systems, procedures, personnel, facilities, equipment, and processes are capable of consistently producing safe and quality drug products.

15. FDA Requested Corrective Actions

In response to the FDA Warning Letter, the firm was asked to provide extensive information and supporting documentation. The requested actions included:

Environmental Monitoring Program

An independent review covering:

Limits
Sampling methods
Sampling locations
Sampling frequency
Trend analysis
Investigation procedures
Adverse trends
CAPA

Manufacturing Design Assessment

A comprehensive assessment of manufacturing operations and microbiological hazards.

Product Risk Assessment

A detailed assessment of risks associated with potentially objectionable microbiological contamination. Potential actions could include:

Customer notification
Product evaluation
Product hold
Market withdrawal
Recall, where appropriate

Batch Investigation

Complete investigations into batches associated with:

Objectionable microorganisms
OOL microbiological results
Environmental excursions
Personnel monitoring excursions

Microbiological Specifications

Appropriate microbiological release specifications for each drug product should be established based on the applicable product and manufacturing process.

Microbiological Testing Methods

The firm should provide the microbiological test methods used for each drug product.

Retain Sample Testing

FDA requested testing of appropriate retain samples from batches within expiry, including relevant quality attributes such as:

Identity
Strength
Microbiological quality
Total microbial counts
Identification of objectionable microorganisms

16. Importance of Data Trending in Environmental Monitoring

One of the key lessons from this FDA Warning Letter is the importance of microbiological data trending. A facility should not only investigate individual excursions but should also evaluate long-term trends. Trending should consider:

Location
Room
Personnel
Organism
Frequency
Magnitude
Time period
Shift
Product
Batch
Intervention
Seasonality, where relevant

Repeated recovery of the same microorganism or recurring contamination patterns should trigger appropriate investigation and risk assessment.

17. Lessons for Pharmaceutical Quality Assurance

This FDA Warning Letter provides important lessons for Quality Assurance and Quality Control professionals.

Environmental Monitoring

The EM program should be capable of detecting contamination hazards before they affect product quality.

Personnel Monitoring

Personnel monitoring should provide meaningful information about operator contamination risk.

Aseptic Technique

Operators must be trained, qualified, observed, and periodically reassessed.

Media Fill

Media fills must represent actual aseptic manufacturing conditions and appropriate worst-case scenarios.

Smoke Studies

Dynamic airflow visualization should demonstrate adequate protection of critical areas.

CAPA

CAPA should address root causes and be verified for effectiveness.

Quality Unit

The Quality Unit must have sufficient authority and independence to identify and address manufacturing risks.

Management Responsibility

Senior management must provide adequate resources and oversight for an effective pharmaceutical quality system.

FDA Warning Letter: Key GMP Lessons

The FDA Warning Letter demonstrates several fundamental principles of sterile pharmaceutical manufacturing:

Sterility must be built into the process.
Environmental monitoring must be scientifically designed and effectively trended.
Repeated microbiological contamination requires comprehensive investigation.
Aseptic interventions must be minimized and appropriately controlled.
Smoke studies must represent dynamic operating conditions.
Media fills must adequately simulate commercial manufacturing.
Facility and equipment design must support contamination control.
Personnel behavior can significantly affect aseptic process control.
CAPA must address systemic root causes.
Quality Unit oversight must be effective and independent.
Management must ensure adequate resources for GMP compliance.
End-product testing cannot replace robust process controls.

Why This FDA Warning Letter Matters to the Pharmaceutical Industry

This FDA Warning Letter is relevant not only to the inspected company but also to sterile pharmaceutical manufacturers worldwide.

For companies supplying products to the United States, United Kingdom, European Union, and other regulated markets, the findings demonstrate the importance of maintaining globally aligned pharmaceutical quality systems.

Although the letter is based on U.S. FDA requirements, many of the underlying quality principles are also highly relevant to international GMP expectations, including:

Contamination control
Aseptic processing
Environmental monitoring
Personnel qualification
Process simulation
Quality Risk Management
CAPA
Data integrity
Quality Unit oversight
Facility and equipment design

Organizations should therefore use regulatory inspection findings as an opportunity to proactively evaluate their own systems.

Conclusion

This FDA Warning Letter identifies serious CGMP deficiencies involving aseptic processing, environmental monitoring, microbiological contamination, facility and equipment design, media fills, smoke studies, personnel practices, CAPA, and Quality Unit oversight.

The repeated recovery of microorganisms from critical ISO 5 environments and the deficiencies in contamination investigations demonstrate the importance of a robust contamination-control strategy.

The findings also show that sterile manufacturing requires much more than passing final-product testing. Facility design, airflow, personnel behavior, environmental monitoring, equipment suitability, process simulation, microbiological controls, and quality oversight must work together to protect sterile products.

Pharmaceutical manufacturers should proactively evaluate their aseptic operations, particularly where recurring environmental monitoring excursions, objectionable microorganisms, media fill failures, airflow deficiencies, or inadequate investigations are observed.

A comprehensive risk assessment, root-cause investigation, CAPA program, qualification and validation strategy, and management oversight system are essential to achieve sustainable GMP compliance.

Reference Warning Letter Date – 09/04/2026 Issued to Bausch & Lomb Inc. for CGMP/Finished Pharmaceuticals/Adulterated by the Center for Drug Evaluation and Research (CDER)Disclaimer

Educational & Awareness Purpose Only:
This article has been prepared for learning, training, educational, and pharmaceutical industry awareness purposes only. The information presented in this article is based on and/or summarized from publicly available information published on the official U.S. Food and Drug Administration (FDA) website, including FDA Warning Letters.

For the original and most up-to-date information, readers should refer directly to the official FDA Warning Letters database and related FDA publications.

This article is not an official FDA publication, communication, guidance, regulatory decision, or statement of the U.S. Food and Drug Administration. PharmGuidances is not affiliated with, endorsed by, or representing the FDA.

The information provided should not be used as a substitute for official FDA documents, applicable laws and regulations, regulatory guidance, legal advice, compliance advice, or professional consultation. It should not be relied upon for making regulatory, legal, manufacturing, quality, or business decisions.

Official Reference:
FDA Warning Letters – U.S. Food and Drug Administration

Post Views: 3